Astria Therapeutics (NASDAQ:ATXS – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.34), Fidelity Earnings reports.
Shares of ATXS stock traded up $0.07 during mid-day trading on Friday, hitting $4.10. 12,866 shares of the company’s stock were exchanged, compared to its average volume of 11,157. Astria Therapeutics has a fifty-two week low of $3.83 and a fifty-two week high of $15.72. The stock has a 50-day simple moving average of $6.27 and a two-hundred day simple moving average of $6.06. The stock has a market cap of $53.38 million, a price-to-earnings ratio of -0.52 and a beta of 1.38.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp raised its position in shares of Astria Therapeutics by 14.3% in the 4th quarter. Northern Trust Corp now owns 22,013 shares of the biotechnology company’s stock worth $119,000 after buying an additional 2,760 shares during the period. UBS Group AG acquired a new position in shares of Astria Therapeutics during the third quarter worth approximately $27,000. Morgan Stanley acquired a new position in shares of Astria Therapeutics during the third quarter worth approximately $28,000. Geode Capital Management LLC raised its holdings in Astria Therapeutics by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 65,014 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 4,484 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Astria Therapeutics during the fourth quarter worth approximately $55,000. 51.79% of the stock is currently owned by institutional investors and hedge funds.
Astria Therapeutics Company Profile (Get Rating)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
- Get a free copy of the StockNews.com research report on Astria Therapeutics (ATXS)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.